|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 102, 904-907, Copyright © 1991 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
HW Pogrebniak, TW Prewitt, WA Matthews and HI Pass
Selected immunotherapies (tumor necrosis factor, interleukin-1,
interleukin-2, and gamma interferon), chemotherapeutic agents (mitomycin,
platinum, doxorubicin [Adriamycin], and bleomycin), and radiation therapy
have been described to exert cytotoxicity through the generation of
reactive oxygen species, including superoxide and hydrogen peroxide. Tumor
necrosis factor, however, has been shown to impart increased resistance in
vitro and in vivo against reactive oxygen species stress, including
radiation therapy and oxygen toxicity, possibly because of the induction of
increased cellular buffering capacities. It is unknown whether the
sensitivity of a lung cancer cell to reactive oxygen species therapy is
altered by tumor necrosis factor through the induction of free radical
scavenging enzymes such as manganese superoxide dismutase. This question
was investigated as follows: A549 lung adenocarcinoma cells, exposed for 24
hours to 0, 0.1, 1.0, or 10 micrograms/ml concentrations of tumor necrosis
factor, were exposed to hypoxanthine plus xanthine oxidase, a superoxide
generating system, for varying intervals. The number of cells surviving 5
days after the stress was determined, and cells exposed to tumor necrosis
factor were examined by Northern Blot analysis for induction of the
manganese superoxide dismutase gene. The hypoxanthine-xanthine oxidase
stress alone caused a time-dependent decrease in survival; however,
pretreatment with tumor necrosis factor increased cell survival
significantly. Moreover, the cells exposed to tumor necrosis factor had a
fivefold increase in the number of manganese superoxide dismutase
transcripts. These findings suggest that tumor necrosis factor may confer
resistance of lung cancer cells to subsequent reactive oxygen species-based
therapies, and the resistance of these cells may be due to increased
expression of manganese superoxide dismutase. Clinical treatment failures
may result, especially if tumor necrosis factor is given concurrently with
other therapies.
ARTICLES
Tumor necrosis factor-alpha alters response of lung cancer cells to oxidative stress
Thoracic Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Md., 20892.
This article has been cited by other articles:
![]() |
J. C.-m. Ho, S. Zheng, S. A. A. Comhair, C. Farver, and S. C. Erzurum Differential Expression of Manganese Superoxide Dismutase and Catalase in Lung Cancer Cancer Res., December 1, 2001; 61(23): 8578 - 8585. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Franek, S. Horowitz, L. Stansberry, J. A. Kazzaz, H.-C. Koo, Y. Li, Y. Arita, J. M. Davis, A. S. Mantell, W. Scott, et al. Hyperoxia Inhibits Oxidant-induced Apoptosis in Lung Epithelial Cells J. Biol. Chem., January 5, 2001; 276(1): 569 - 575. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |